Abstract
Type 2 diabetes mellitus (T2DM) accounts for 90%–95% of all diabetes cases. The overarching goal in caring for patients with T2DM is to prevent microvascular and macrovascular complications with glycemic control. Several studies such as UKPDS, DCCT, and EDIC have been performed to evaluate the effects of glucose control on tissue complications in patients with diabetes. In recent diabetes trials including ACCORD, ADVANCE, VADT, BARI 2D, and ORIGIN, intensive glucose control did not prevent macrovascular complications in older patients with long-standing diabetes with either cardiovascular disease or risk factors for cardiovascular disease. In fact, intensive therapy was associated with increased mortality in the ACCORD trial. Although no clear macrovascular benefit was seen in these trials, analyses of earlier studies in younger patients with type 1 and type 2 diabetes have suggested a significant benefit of intensive glycemic control in patients with a shorter duration of diabetes and less vasculopathy. In the UKPDS, the incidence of microvascular disease, particularly retinopathy, was reduced significantly with intensive glucose control, but in the more recent trials (ACCORD, ADVANCE, VADT, ORIGIN) the benefit was relatively modest and limited to reduced proteinuria. Perhaps the most important message from the above trials is to optimize control of cardiovascular risk factors. Although the goal HbA1c to prevent microvascular and macrovascular complications, per the American Diabetes Association, is less than 7%, hypoglycemia should be avoided as it can increase the risk for severe cardiovascular events.
Keywords: ACCORD, ADVANCE, BARI 2D, diabetes trials, intensive glycemic control, macrovascular disease, ORIGIN, VADT.
Current Diabetes Reviews
Title:An Insight into the Recent Diabetes Trials: What is the Best Approach to Prevent Macrovascular and Microvascular Complications?
Volume: 9 Issue: 5
Author(s): Manige Konig, Elizabeth Mary Lamos, Stephanie Aleskow Stein and Stephen N. Davis
Affiliation:
Keywords: ACCORD, ADVANCE, BARI 2D, diabetes trials, intensive glycemic control, macrovascular disease, ORIGIN, VADT.
Abstract: Type 2 diabetes mellitus (T2DM) accounts for 90%–95% of all diabetes cases. The overarching goal in caring for patients with T2DM is to prevent microvascular and macrovascular complications with glycemic control. Several studies such as UKPDS, DCCT, and EDIC have been performed to evaluate the effects of glucose control on tissue complications in patients with diabetes. In recent diabetes trials including ACCORD, ADVANCE, VADT, BARI 2D, and ORIGIN, intensive glucose control did not prevent macrovascular complications in older patients with long-standing diabetes with either cardiovascular disease or risk factors for cardiovascular disease. In fact, intensive therapy was associated with increased mortality in the ACCORD trial. Although no clear macrovascular benefit was seen in these trials, analyses of earlier studies in younger patients with type 1 and type 2 diabetes have suggested a significant benefit of intensive glycemic control in patients with a shorter duration of diabetes and less vasculopathy. In the UKPDS, the incidence of microvascular disease, particularly retinopathy, was reduced significantly with intensive glucose control, but in the more recent trials (ACCORD, ADVANCE, VADT, ORIGIN) the benefit was relatively modest and limited to reduced proteinuria. Perhaps the most important message from the above trials is to optimize control of cardiovascular risk factors. Although the goal HbA1c to prevent microvascular and macrovascular complications, per the American Diabetes Association, is less than 7%, hypoglycemia should be avoided as it can increase the risk for severe cardiovascular events.
Export Options
About this article
Cite this article as:
Konig Manige, Lamos Mary Elizabeth, Stein Aleskow Stephanie and Davis N. Stephen, An Insight into the Recent Diabetes Trials: What is the Best Approach to Prevent Macrovascular and Microvascular Complications?, Current Diabetes Reviews 2013; 9 (5) . https://dx.doi.org/10.2174/15733998113099990077
DOI https://dx.doi.org/10.2174/15733998113099990077 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monocyte Cyclooxygenase-2 Activity: A New Therapeutic Target for Atherosclerosis?
Current Drug Targets - Cardiovascular & Hematological Disorders Vaccine Development for Group A Streptococcus Infections and Associated Diseases
Current Drug Targets Causes of Impaired Fertility in Women with Polycystic Ovary Syndrome
Current Women`s Health Reviews Tobacco Smoking and Association between Betel Nut Chewing and Metabolic Abnormalities Among Military Males: The CHIEF Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Treatment of Atherosclerotic Renovascular Disease
Current Hypertension Reviews Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS
Current Pharmaceutical Design Mood Stabilizers, Oxidative Stress and Antioxidative Defense in Euthymia of Bipolar Disorder
CNS & Neurological Disorders - Drug Targets Pharmacological Therapy in Children with Atrial Fibrillation and Atrial Flutter
Current Pharmaceutical Design Cardiac Specific Overexpression of hHole Attenuates Isoproterenol–Induced Hypertrophic Remodeling through Inhibition of Extracellular Signal-Regulated Kinases (ERKs) Signalling
Current Molecular Medicine Procyanidins and Their Healthy Protective Effects Against Type 2 Diabetes
Current Medicinal Chemistry Abeta Immunotherapy and Other Means to Remove Amyloid
Current Drug Targets - CNS & Neurological Disorders Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry Sildenafil is Well Tolerated by Erectile Dysfunction Patients Taking Antihypertensive Medications, Including Those on Multidrug Regimens
Current Drug Safety Q Fever Endocarditis
Infectious Disorders - Drug Targets Foreword [The Largest Unmet Market: Chronic Diseases of Aging]
Mini-Reviews in Medicinal Chemistry Association between Antiretroviral Treatment and Markers of Systemic Inflammation among HIV Patients in Ghana
Current HIV Research Inducers of Heme Oxygenase-1
Current Pharmaceutical Design Stage A: Can Heart Failure Be Prevented?
Current Cardiology Reviews Dietary Fish Oil Concentrates Associated Health Benefits: A Recent Development of Cardiovascular Risk Reduction
Current Pharmaceutical Design Insulin Resistance in the Early Stages of Renal Failure: Implications for Cardiovascular Risk
Current Diabetes Reviews